Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$27.62-6.05%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for AMLX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Develop AMX0318 for rare diseases | It is developing a new drug candidate AMX0318 for rare diseases. | Intact | AMX0318 development stalls or is discontinued | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative growth-stage biotech, not a proven earnings compounder. The long-term thesis is in a watch state: the LUCIDITY trial delivered positive results, but the business remains loss-making and confidence in the assessment is low.
The snapshot provides no valuation measure or clear account of what the market expects, so valuation and the expectations gap cannot be assessed reliably. It reports no pricing-fragility warning, but that does not establish that the shares are cheap or that trial success is fully reflected.
Near term, the company is likely to remain loss-making as it advances regulatory and commercial readiness; cash declined between the first and second quarters of 2026, while management still expects runway into 2028. The Phase 3 trial met its primary and secondary endpoints, with a 55% reduction in hypoglycemic events, but earnings misses, litigation filings, and elevated risk leave execution uncertain.
The multi-year thesis hinges on submitting the avexitide NDA by the end of 2026 and, if approved, launching in 2027. A guidance cut or further weakening in jobs data could add pressure, while continued strength among Healthcare bellwethers could support sector momentum.
Over the next 1 to 3 years, AMLX has a meaningful clinical milestone behind it, but approval, launch execution, ongoing losses, and low confidence make the long-term thesis uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company aims to maintain cash runway into 2028. |
| Improving |
| Cash runway falls short of 2028 based on operating plans |
Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Based on its current operating plans, Amylyx expects a cash runway into 2028.” “Cash Position: Cash, cash equivalents, and short-term investments were $250.8 million at June 30, 2026, compared to $279.8 million at March 31, 2026.” Delivery assessment Nov 4, 2026 |
Reduce losses toward break-even | A primary condition in Amylyx Pharmaceuticals, Inc.'s published investment case. The stated target is EPS improves from -$0.46 in 2025 toward break-even. | Improving | EPS remains below -$0.46 or worsens through FY27 | Diluted EPS: $-0.39 per share FY2026-Q2; GAAP. Published target: EPS improves from -$0.46 in 2025 toward break-even. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026-0.39 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.26 → $-1.13 · observed estimates
$0.04B → $0.06B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.26 | $38,996,660 | 8 / 10 |
| 2026-07-25 | $-1.26 | $38,996,660 | 8 / 10 |
| 2026-07-26 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-07-27 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-07-28 | $-1.34 | $33,030,904 | 6 / 6 |
| 2026-07-29 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-07-30 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-07-31 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-01 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-02 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-03 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-04 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-05 | $-1.36 | $29,364,070 | 7 / 9 |
| 2026-08-06 | $-1.36 | $29,423,470 | 7 / 9 |
| 2026-08-07 | $-1.34 | $33,097,732 | 6 / 6 |
| 2026-08-08 | $-1.34 | $33,101,410 | 7 / 8 |
| 2026-08-09 | $-1.34 | $34,404,020 | 7 / 8 |
| 2026-08-10 | $-1.34 | $34,404,020 | 7 / 8 |
| 2026-08-11 | $-1.38 | $29,313,000 | 7 / 6 |
| 2026-08-12 | $-1.38 | $29,313,000 | 7 / 6 |
| 2026-08-13 | $-1.38 | $32,043,250 | 7 / 9 |
| 2026-08-14 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-15 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-16 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-17 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-18 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-19 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-20 | $-1.35 | $32,043,252 | 6 / 6 |
| 2026-08-21 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-22 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-23 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-24 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-25 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-26 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-27 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-28 | $-1.20 | $56,197,107 | 7 / 7 |
| 2026-08-29 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-08-30 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-08-31 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-01 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-02 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-03 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-04 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-05 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-06 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-07 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-08 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-09 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-10 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-11 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-12 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-13 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-14 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-15 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-16 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-17 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-18 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-19 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-20 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-21 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-22 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-23 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-24 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-25 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-26 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-27 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-28 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-29 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-09-30 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-01 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-02 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-03 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-04 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-05 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-06 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-07 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-08 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-09 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-10 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-11 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-12 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-13 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-14 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-15 | $-1.18 | $56,487,107 | 7 / 7 |
| 2026-10-16 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-17 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-18 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-19 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-20 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-21 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-22 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-23 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-24 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-25 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-26 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-27 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-28 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-29 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-30 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-10-31 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-11-01 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-11-02 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-11-03 | $-1.13 | $56,549,480 | 7 / 7 |
| 2026-11-04 | $-1.13 | $56,549,480 | 7 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.